Turn Therapeutics Inc
NASDAQ:TTRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (22.2), the stock would be worth $0 (100% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $3.69 |
0%
|
| Industry Average | 22.2 | $0 |
-100%
|
| Country Average | 21.9 | $0 |
-100%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
Turn Therapeutics Inc
NASDAQ:TTRX
|
108.7m USD | 0 | 0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
291.1B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
56B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.6B USD | 45.2 | -3 246.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
Other Multiples
Turn Therapeutics Inc
Glance View
Turn Therapeutics, Inc. focuses on solving massive health problems by eliminating diseases and strengthening health systems through powerful partnerships and operational research. The company is headquartered in Westlake Village, California. The company went IPO on 2025-10-08. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
